With improved awareness and screening, earlier diagnosis and intervention are becoming more achievable, especially with the support of emerging biomarkers and treatment guidelines. Innovative therapies such as HIF-PH inhibitors and long-acting erythropoiesis-stimulating agents (ESAs) are shaping a dynamic treatment landscape aimed at improving hemoglobin levels with fewer side effects.
DelveInsight’s “Anemia in Chronic Kidney Disease Market Report” offers an in-depth analysis of the epidemiology, disease burden, and market outlook across key geographies, including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report highlights current unmet needs, late-stage pipeline therapies, market drivers and barriers, and the key players transforming patient care, making it a vital resource for healthcare stakeholders and innovators in nephrology.
Some of the Key Facts of the Anemia in Chronic Kidney Disease Market Report:
• The anemia in chronic kidney disease is expected to grow at a significant CAGR by 2034.
• In 2023, the United States recorded the highest number of prevalent Anemia in Chronic Kidney Disease (CKD) cases among the 7MM.
• The U.S. also accounted for the highest number of treated cases of Anemia in CKD during the same year.
• A higher prevalence was noted among individuals aged 60 and above compared to those under 60 in the U.S.
• Males with CKD had a 30% higher risk of developing anemia compared to females.
• Among the EU4 and the UK, Spain reported the lowest number of anemia in CKD cases in 2023.
• In Japan, anemia was one of the most frequently documented outcomes, with prevalence rates ranging from 0% to 95%, depending on CKD severity and dialysis status.
• In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome.
• In March 2025, scPharmaceuticals received FDA approval for a supplemental new drug application (sNDA) for Furoscix (furosemide injection). This approval expands the drug’s use to treat edema in patients with chronic kidney disease (CKD), marking a significant advancement in scPharmaceuticals’ portfolio for cardiorenal conditions.
• In March 2025, the FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is expected to be available by April 2025. This approval follows the FDA’s acceptance of the supplemental new drug application in July 2024.
• In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk.
• In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a PDUFA target action date set for June 28, 2025. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis.
• Leading companies in the anemia in chronic kidney disease market include Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others.
• Emerging therapies in the anemia in chronic kidney disease market include DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others.
• The rising prevalence of anemia in chronic kidney disease, along with continuous advancements in therapeutic options, is fueling the demand for more effective treatment approaches.
To know in detail about the anemia in chronic kidney disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Anemia In Chronic Kidney Disease Market Forecast
Anemia in Chronic Kidney Disease Overview
Anemia is a frequent and serious complication of Chronic Kidney Disease (CKD), arising as kidney function declines and the body’s ability to produce adequate erythropoietin—a hormone essential for red blood cell production, diminishes. CKD impairs the kidneys’ filtering ability, leading to the accumulation of waste and fluids, which further contributes to the onset of anemia.
The condition becomes increasingly prevalent in advanced stages of CKD. In the United States, over 37 million adults are estimated to have CKD, and more than one in seven individuals with CKD also suffer from anemia. The risk intensifies as kidney function deteriorates, with nearly all individuals at end-stage kidney failure (when kidney function drops below 15%) experiencing anemia.
Certain populations are more susceptible: individuals with CKD and diabetes are at higher risk of developing anemia earlier and in more severe forms. Additionally, people over the age of 60 are more likely to be affected. The progression of CKD-related anemia is typically gradual and may remain asymptomatic in its early stages, making early detection and management crucial for improving patient outcomes.
Get a free sample of the anemia in chronic kidney disease market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
Anemia in Chronic Kidney Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Anemia in Chronic Kidney Disease Epidemiology Segmentation:
The anemia in chronic kidney disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total Prevalent Cases of Chronic Kidney Disease
• Diagnosed Cases of Anemia in Chronic Kidney Disease
• Age-Specific Prevalent Cases of Anemia in Chronic Kidney Disease
• Total Prevalent Cases of Anemia in Chronic Kidney Disease
• Total Prevalent Cases of Anemia in Different Stages of Chronic Kidney Disease
• Treatable Cases of Anemia in Chronic Kidney Disease
Download the report to understand which factors are driving anemia in chronic kidney disease epidemiology trends @ Anemia In Chronic Kidney Disease Epidemiology Forecast
Anemia in Chronic Kidney Disease Drugs Uptake and Pipeline Development Activities
The anemia in chronic kidney disease drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the anemia in chronic kidney disease market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.
Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.
The report further delves into the anemia in chronic kidney disease pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.
Anemia in Chronic Kidney Disease Market Strengths
• The availability of novel oral treatment options, such as daprodustat, offers more convenient and effective routes of administration for patients.
• Active research and ongoing clinical trials are enhancing the understanding of the disease and driving innovation in therapeutic strategies.
Anemia in Chronic Kidney Disease Market Weaknesses
• Patients often struggle to recognize or differentiate the symptoms of anemia from CKD or other related conditions, leading to underreporting.
• Healthcare providers, particularly in non-dialysis settings, frequently under-monitor hemoglobin levels and iron stores, resulting in delayed or suboptimal treatment initiation.
Scope of the Anemia in Chronic Kidney Disease Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Anemia In Chronic Kidney Disease Companies: GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others.
• Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, SSS17, BCD-131, BCD-066, Erythropoietin polysialic, CHIP 2, PBI 1402, Sotatercept, and others.
• Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia in chronic kidney disease, currently marketed, and anemia in chronic kidney disease emerging therapies
• Anemia In Chronic Kidney Disease Market Dynamics: Anemia in chronic kidney disease market drivers and anemia in chronic kidney disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Anemia In Chronic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Anemia In Chronic Kidney Disease Market Access and Reimbursement
To learn more about the key players and advancements in the anemia in chronic kidney disease treatment landscape, visit the Anemia In Chronic Kidney Disease Market Analysis Report
Table of Contents
1. Anemia In Chronic Kidney Disease Market Report Introduction
2. Executive Summary for Anemia In Chronic Kidney Disease
3. SWOT analysis of Anemia In Chronic Kidney Disease
4. Anemia In Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Anemia In Chronic Kidney Disease Market Overview at a Glance
6. Anemia In Chronic Kidney Disease Disease Background and Overview
7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Anemia In Chronic Kidney Disease
9. Anemia In Chronic Kidney Disease Current Treatment and Medical Practices
10. Anemia In Chronic Kidney Disease Unmet Needs
11. Anemia In Chronic Kidney Disease Emerging Therapies
12. Anemia In Chronic Kidney Disease Market Outlook
13. Country-Wise Anemia In Chronic Kidney Disease Market Analysis (2020–2034)
14. Anemia In Chronic Kidney Disease Market Access and Reimbursement of Therapies
15. Anemia In Chronic Kidney Disease Market Drivers
16. Anemia In Chronic Kidney Disease Market Barriers
17. Anemia In Chronic Kidney Disease Appendix
18. Anemia In Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Jatin VimalEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
